Search Results - Elisabeth I. Heath

Refine Results
  1. 1
    Angiogenesis inhibitors in the treatment of prostate cancer

    Angiogenesis inhibitors in the treatment of prostate cancer by Clara Hwang, Elisabeth I. Heath

    Published 2010
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Prostate cancer dormancy and recurrence

    Prostate cancer dormancy and recurrence by Frank C. Cackowski, Elisabeth I. Heath

    Published 2021
    Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes

    Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes by Dejuan Kong, Seema Sethi, Yiwei Li, Wei Chen, Wael Sakr, Elisabeth I. Heath, Fazlul H. Sarkar

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

    Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinu... by Shirish M. Gadgeel, John C. Ruckdeschel, Elisabeth I. Heath, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Antoinette J. Wozniak

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer

    Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer by Lauren M. Hamel, Louis A. Penner, Terrance L. Albrecht, Elisabeth I. Heath, Clement K. Gwede, Susan Eggly

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Galectin-3: a possible complementary marker to the PSA blood test

    Galectin-3: a possible complementary marker to the PSA blood test by Vitaly Balan, Yi Wang, Pratima Nangia‐Makker, Dhonghyo Kho, Madhuri Bajaj, Daryn Smith, Lance K. Heilbrun, Avraham Raz, Elisabeth I. Heath

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis

    Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis by M. Katie Conley‐LaComb, Louie Semaan, Rajareddy Singareddy, Yanfeng Li, Elisabeth I. Heath, Seongho Kim, Michael L. Cher, Sreenivasa R. Chinni

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

    Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial by Przemyslaw Twardowski, Walter M. Stadler, Paul Frankel, Primo N. Lara, Christopher Ruel, Gurkamal Chatta, Elisabeth I. Heath, David I. Quinn, David R. Gandara

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients

    Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients by Amitabh Chak, Marcia I. Canto, Gregory S. Cooper, Gerard Isenberg, Joseph Willis, Nathan Levitan, Julie Clayman, Arlene A. Forastiere, Elisabeth I. Heath, Michael Sivak

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

    Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy by Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth I. Heath, Joseph A. Fontana, Ulka N. Vaishampayan

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Prostate Tumor Cell–Derived IL1β Induces an Inflammatory Phenotype in Bone Marrow Adipocytes and Reduces Sensitivity to Docetaxel via Lipolysis-Dependent Mechanisms

    Prostate Tumor Cell–Derived IL1β Induces an Inflammatory Phenotype in Bone Marrow Adipocytes and Reduces Sensitivity to Docetaxel via Lipolysis-Dependent Mechanisms by Mackenzie K. Herroon, Jonathan D. Diedrich, Erandi Rajagurubandara, Carly Martin, Krishna Rao Maddipati, Seongho Kim, Elisabeth I. Heath, James G. Granneman, Izabela Podgorski

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Smartphone apps for cancer: A content analysis of the digital health marketplace

    Smartphone apps for cancer: A content analysis of the digital health marketplace by Deborah H. Charbonneau, Shonee Hightower, Anne Katz, Ke Zhang, Judith Abrams, Nicole Senft, Jennifer Beebe‐Dimmer, Elisabeth I. Heath, Tara Eaton, Hayley S. Thompson

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Racial Disparities in the Molecular Landscape of Cancer

    Racial Disparities in the Molecular Landscape of Cancer by Elisabeth I. Heath, Filipa Lynce, Joanne Xiu, Angela Ellerbrock, Sandeep K. Reddy, Elias Obeid, Stephen V. Liu, Aliccia Bollig‐Fischer, Duška Šeparović, Ari M. Vanderwalde

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

    A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 by Naomi B. Haas, Xinyi Lin, Judith Manola, Michael Pins, Glenn Liu, David F. McDermott, David M. Nanus, Elisabeth I. Heath, George Wilding, Janice P. Dutcher

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Soy Isoflavones in Conjunction With Radiation Therapy in Patients With Prostate Cancer

    Soy Isoflavones in Conjunction With Radiation Therapy in Patients With Prostate Cancer by Iftekhar Ahmad, Jeffrey D. Forman, Fazlul H. Sarkar, Gilda G. Hillman, Elisabeth I. Heath, Ulka N. Vaishampayan, Michael L. Cher, Fundagül Andiç, Peter J. Rossi, Ömer Küçük

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study

    A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate canc... by Manish Thakur, Lance K. Heilbrun, Shijie Sheng, Mark N. Stein, Glenn Liu, Emmanuel S. Antonarakis, Ulka N. Vaishampayan, Sijana H. Dzinic, Xiaohua Li, Stacy Freeman, Daryn Smith, Elisabeth I. Heath

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

    Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer by Anthony V. Serritella, Daniel H. Shevrin, Elisabeth I. Heath, James L. Wade, Elia Martinez, Amanda Anderson, Joseph D. Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M. Stadler, Russell Z. Szmulewitz

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial

    Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized Trial by Elisabeth I. Heath, Marcia I. Canto, Steven Piantadosi, Elizabeth A. Montgomery, W.M. Weinstein, James G. Herman, Andrew J. Dannenberg, Vincent W. Yang, Albert O. Shar, Ernest T. Hawk, Arlene A. Forastiere

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors

    Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors by Patricia LoRusso, Martin J. Edelman, S. Bever, Karen Forman, MaryJo Pilat, Mary Flanagan Quinn, Jing Li, Elisabeth I. Heath, Lisa Malburg, Patrick Klein, Christopher P. Leamon, Richard A. Messmann, Edward A. Sausville

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    The current state of molecular testing in the treatment of patients with solid tumors, 2019

    The current state of molecular testing in the treatment of patients with solid tumors, 2019 by Wafik S. El‐Deiry, Richard M. Goldberg, Heinz‐Josef Lenz, Anthony F. Shields, Geoffrey T. Gibney, Antoinette R. Tan, Jubilee Brown, Burton Eisenberg, Elisabeth I. Heath, Surasak Phuphanich, Edward Kim, Andrew Brenner, John L. Marshall

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: